What Is Vencur IV 10 mg/vial Indications and Uses?

Vencur is indicated as an adjunct to general anaesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Pharmacology (Source, Chemical and Physical Composition) Of Vencur IV 10 mg/vial

Vencur IV 10 mg/vial (Vecuronium Bromide) is a preparation of Vecuronium Bromide. It is a Lyophilized powder for injection. It is a non-depolarising neuromuscular blocking agent. Vecuronium Bromide blocks the transmission process between the motor nerve-ending and striated muscle by binding competitively with acetylcholine to the nicotinic receptors located in the motor end-plate region of striated muscle.

Drug Interactions of Vencur IV 10 mg/vial

Succinylcholine : Prior administration of succinylcholine may enhance the neuromuscular blocking effect of Vencur and its duration of action. If succinylcholine is used before Vencur, the administration of Vencur should be delayed until the succinylcholine effect shows signs of wearing off. With succinylcholine as the intubating agent, initial doses of 0.04 to 0.06 mg/kg of Vencur IV 10 mg/vial (Vecuronium Bromide) may be administered to produce complete neuromuscular block with clinical duration of action of 25 to 30 minutes. Other nondepolarizing neuromuscular blocking agents (pancuronium, d-tubocurarine, metocurine and gallamine) act in the same fashion as does Vencur; therefore, these drugs and Vencur may manifest an additive effect when used together. Inhalation Anesthetics : Use of volatile inhalational anesthetics such as enflurane, isoflurane, and halothane with Vencur will enhance neuromuscular blockade. Antibiotics : Parenteral/intraperitoneal administration of high doses of certain antibiotics may intensify or produce a neuromuscular block on their own. The following antibiotics have been associated with various degrees of paralysis: aminoglycosides (such as neomycin, streptomycin, kanamycin, gentamicin, and dihydrostreptomycin); tetracyclines; bacitracin; polymyxin B; colistin; and sodium colistimethate. If these or other newly introduced antibiotics are used in conjunction with vecuronium during surgery, unexpected prolongation of neuromuscular block should be considered a possibility. Other : Experience concerning injection of quinidine during recovery from use of other muscle relaxants suggests that recurrent paralysis may occur. This possibility must also be considered for vecuronium. Vencur induced neuromuscular blockade has been counteracted by alkalosis and enhanced by acidosis in experimental animals (cat). Electrolyte imbalance and diseases which lead to electrolyte imbalance, such as adrenal cortical insufficiency, have been shown to alter neuromuscular blockade. Depending on the nature of the imbalance, either enhancement or inhibition may be expected. Magnesium salts, administered for the management of toxemia of pregnancy, may enhance neuromuscular blockade.

Side Effects of Vencur IV 10 mg/vial

Vencur is a non-depolarising muscle relaxants, has an intermediate duration of action. It does not generally produce histamine release and lacks cardiovascular effects. The common side effects of non-depolarising muscle relaxants are skin flushing, hypotension, tachycardia, bronchospasm and very rarely, anaphylactoid reactions. Acute myopathy has also been reported after prolonged use in intensive care.

Precautions And Warnings for Vencur IV 10 mg/vial

Allergic cross-reactivity between neuromuscular blocking agents has been reported; caution is advised in cases of hypersensitivity to these drugs. Their activity is prolonged in patients with myasthenia gravis and in hypothermia, therefore lower doses are required. Non-depolarising muscle relaxants should be used with great care in those with other neuromuscular disorders and those with fluid and electrolyte disturbances, as response is unpredictable. Resistance may develop in patients with burns who may require increased doses; low plasma cholinesterase activity in these patients requires dose titration for mivacurium. General : Vencur should be administered in carefully adjusted dosage by or under the supervision of experienced clinicians who are familiar with its actions and the possible complications that might occur following its use. The drug should not be administered unless facilities for intubation, artificial respiration, oxygen therapy, and reversal agents are immediately available. The clinician must be prepared to assist or control respiration. A peripheral nerve stimulator should be employed to monitor drug response, need for additional relaxant, and adequacy of spontaneous recovery or anticholinesterase antagonism. Intensive Care Unit : To reduce the possibility of prolonged neuromuscular blockade and other complications that might occur following long-term use in the ICU, Vencur or any other neuromuscular blocking agent should be administered in carefully adjusted doses by or under the supervision of experienced clinicians who are familiar with its actions and with appropriate peripheral nerve stimulator muscle monitoring techniques. Neuromuscular Disease : In patients who are known to have myasthenia gravis or the myasthenic syndrome, small doses of Vencur may have profound effects. In such patients, a peripheral nerve stimulator and use of a small test dose may be of particular value in assessing and monitoring dosage requirements.

Use During Pregnancy and Lactation

There are insufficient data on the use of Vencur IV 10 mg/vial (Vecuronium Bromide) during animal or human Pregnancy to assess potential harm to the foetus. Vecuronium should be given to a pregnant woman only when the attending physician decides that the benefits outweigh the risks. There are no human data on the use of Vecuronium during lactation. Vecuronium should be given to lactating women only when the attending physician decides that the benefits outweigh the risks. Caesarean section: Studies with Vecuronium, administered in doses up to 0.1 mg/kg, have shown its safety for use in caesarean section. In caesarean section the dose should not exceed 0.1 mg/kg. In several clinical studies Vecuronium did not affect Apgar score, foetal muscle tonus or cardio respiratory adaptation. From umbilical cord blood sampling it is apparent that only very little placental transfer of vecuronium occurs which did not lead to the observation of any clinical adverse effect in the newborn.

Therapeutic Class

Non depolarizing muscle relaxants

Storage Conditions of It

Store in a cool and dry place. Protect from light. Keep out of the reach of children. Pack Images: Vencur 10 mg Injection Thanks for using MedEx! How would you rate your experience so far?